KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.

Kristin A Shimano, Amanda B Grimes, Shipra Kaicker, Sanjay J Shah, Elizabeth Gunn, Rukhmi V Bhat, Manpreet Kochhar, Jennifer A Rothman, Melissa J Rose, Michael Briones, Taizo A Nakano, Jeffrey D Lebensburger, Michele P Lambert, Stephanie A Fritch Lilla, Rohith Jesudas, Cathy A Lee-Miller, Alexis A Thompson, Stacey Rifkin-Zenenberg, Suvankar Majumdar, Shelley E Crary, Kerry Hege, James B Ford, Joshua J Bies, John Fort, Tung T Wynn, Loan Hsieh, Maritza E Ruiz, Bogdan Dinu, Julia M W Wong, Pei-Chi Kao, Taylor O Kim, Staci D Arnold, Carolyn M Bennett, Jenny M Despotovic, Robert J Klaassen, Ellis J Neufeld, Cindy E Neunert, Wendy B London, Rachael F Grace

JAMA 334(20) 1816-1826

PMID41123939
PMCIDPMC12547676
DOI10.1001/jama.2025.18168
发表日期2025-10-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown. OBJECTIVE: To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed immune thrombocytopenia treated with eltrombopag than in those treated with standard therapy (first-line treatments). DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized clinical trial enrolled patients (aged 1-<18 years) with newly diagnosed primary immune thrombocytopenia (platelet count <30 × 109/L who required pharmacological treatment but did not have severe bleeding or need a rapid increase in platelet count) from May 7, 2019, to January 25, 2024, at 23 centers participating in the Pediatric ITP Consortium of North America. Final follow-up occurred on February 26, 2025. INTERVENTIONS: Eltrombopag was administered orally based on a standard dosing schedule (n = 78) vs standard therapy (investigator choice of glucocorticoids, intravenous immunoglobulin, or anti-D immunoglobulin) (n = 40). MAIN OUTCOMES AND MEASURES: The primary outcome was a sustained platelet response defined as 3 or more of 4 platelet counts greater than 50 × 109/L during weeks 6 to 12 without rescue treatment. The secondary outcomes included bleeding scores, change in health-related quality of life, and serious adverse events. RESULTS: Of 118 pediatric patients (median age, 8 years [IQR, 4-12 years]; 49% were male), 63% experienced an initial treatment failure after observation or medical therapy. Enrollment ended after a planned interim analysis met a prespecified threshold for efficacy. Of 71 patients in the eltrombopag group, 46 (65% [95% CI, 54%-76%]) had a sustained platelet response compared with 13 of 37 patients (35% [95% CI, 20%-51%]) in the standard therapy group (between-group difference, 30% [95% CI, 11%-49%]; P = .002), which crossed the monitoring boundary for efficacy. Overall, there was no between-group difference in the number and type of adverse events. CONCLUSIONS AND RELEVANCE: In pediatric patients with newly diagnosed immune thrombocytopenia requiring pharmacological treatment, eltrombopag resulted in a higher rate of sustained platelet response compared with standard therapy. Eltrombopag may be an effective option for pediatric patients with newly diagnosed immune thrombocytopenia with nonsevere bleeding who warrant medical intervention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03939637.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Treatment Comparison Across Efficacy and Patient-Reported Outcomes A, The error bars represent the 95% CIs. a The World Health Organization (WHO) Bleeding Scale ranges from a score of 0 (no bleeding) to 4 (debilitating blood loss). The Buchanan-Adix Scale ranges from a score of 0 (no bleeding) to 5 (life threatening or fatal). B, An event is the first occurrence of rescue therapy or receipt of prohibited therapy (patients were censored on the date of last contact or at 12 weeks, whichever occurred first). HR indicates hazard ratio. The HRs were calculated to represent the median cumulative incidence. Some patients had the 12-week visit after day 84 (time point assessment window was ± 7 days); however, the incidence curves were truncated at 84 days so data after day 84 are not shown. The shaded areas indicate the 95% CIs. C and D, The boxes represent first and third quartiles; the white circles represent the mean; the black lines within the boxes represent the median; the whiskers represent the upper and lower boundaries at 1.5 × the IQR; and the blue and orange circles represent the outliers. C, The summary scores are reported on a scale from 0 (worst) to 100 (best possible quality of life). The minimally important difference in the change from baseline was defined a priori as 0.5 × SD of the baseline score. The minimally important difference was 7.15 in the overall cohort. The baseline mean parent-proxy–reported Kids’ ITP Tool score plus the minimally important difference was 78.65 in the eltrombopag group and 83.35 in the standard therapy group. D, The platelet counts measured after a patient started rescue therapy were excluded from the analysis.

B

rescue therapy or prohibited treatment

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Eligibility, Enrollment, Randomization, and Flow of Patients Through the Trial a Eligible patients were randomized 2:1 to receive eltrombopag or standard therapy (investigator choice of glucocorticoids, intravenous immunoglobulin, or anti-D immunoglobulin). Randomization was stratified by age at enrollment (age cohorts: 1-<6, 6-<12, and 12-<18 years) and whether the patient was enrolled upfront (within 10 days of diagnosis and no prior pharmacological treatment) or after experiencing an initial treatment failure (with the standard therapies listed above or observation). b Patients received at least 1 dose of treatment during the study. c A total of 108 patients (two-thirds of planned trial accrual) were included.
非 KM Figure